Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

The HER3-directed ADC will be tested in patients whose disease had progressed despite earlier treatment with EGFR inhibitors, including third-generation drugs like AZ's Tagrisso (osimertinib).

Trastuzumab, a humanized monoclonal antibody directed against the extracellular domain of the HER2 receptor, and lapatinib, a dual reversible EGFR/HER2 TKI, are indicated for the treatment of HER2 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The European Commission has approved Daiichi Sankyo and AstraZeneca's Enhertu as the first targeted therapy for HER2-low breast cancer, unlocking a large population of patients who could be ...

没有更多了 ...